Specifically, 53% (n = 9/17) had no previously reported driver of resistance, and 35% (n = 6/17) had a mutation in a gene previously implicated in acquired resistance (B2M or JAK1/2) that was expected to be deleterious and changed in cancer cell fraction (CCF) (Figure 3B). This evidence concerns the gene B2M and cancer.